Navigation Links
CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
Date:11/21/2008

MAIDENHEAD, England, November 21 /PRNewswire-FirstCall/ --

- Not for UK Journalists

The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and over and adolescents with severe plaque psoriasis. If approved by the European Commission, following the Committee's recommendation, Enbrel will become the first biologic treatment indicated for severe psoriasis in children and adolescents. Enbrel is currently approved in the European Union for the treatment of moderate-to-severe plaque psoriasis in adults, as well as for ankylosing spondylitis, psoriatic arthritis, moderate to severe rheumatoid arthritis (RA) in adults, and polyarticular juvenile idiopathic arthritis (JIA) in children.(1)

"Psoriasis can be a distressing disease at any age," said Stevo Knezevic, MD, PhD, Chief Medical Officer of Wyeth Europa. "A third of psoriasis patients first see signs of the disease well before the age of 16 and there are currently limited effective treatment options available with approved dosing regimens for children and adolescents. We are, therefore, encouraged by the positive recommendation from the CHMP for the approval of Enbrel(R) for use in the paediatric population."

The recommendation by the CHMP is based on results from the first randomised placebo-controlled trial of a biologic treatment in children aged 17 and under (study 211). Results from the study showed that patients treated with Enbrel experienced a significant improvement of their plaque psoriasis compared to those treated with placebo. There were no serious adverse events or serious infections during the 12-week placebo-controlled period and rates of adverse events were similar for Enbrel and placebo.

Impact of Psoriasis

Across Europe, 5.1 million people are estimated to h
'/>"/>

SOURCE Wyeth Pharmaceuticals Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Task Force Recommends Screening for Hearing Loss in All Newborns
2. FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
3. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. CHMP Recommends Expanded Use of Angiox(R) (Bivalirudin) in Europe for Patients With Acute Coronary Syndromes
6. Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
7. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
10. Sunshine Heart Announces IDE Approval To Begin C-Pulse U.S. Clinical Feasibility Trial
11. Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/23/2014)... the depletion of self-control, according to research published in ... for Psychological Science. , Self-control can be difficult ... on a boring textbook are hard things to do. ... Exerting self-control for a long period seems to "deplete" ... , "It is as if self-control is a limited ...
(Date:4/22/2014)... a popular high school sport in the United States ... by researchers in the Center for Injury Research and ... compare and describe the occurrence and distribution patterns of ... school athletic training setting among adolescents and teens. , ... Athletic Training , examined data relating to adolescents 13-19 ...
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
(Date:4/22/2014)... percent of all lung cancers are small cell ... develop resistance to chemotherapy. However, researchers at Virginia ... insights into the mechanisms leading to this resistance ... Chemotherapies work primarily by mediating B-cell lymphoma 2 ... cell death. Depending on their function, this family ...
(Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
Breaking Medicine News(10 mins):Health News:ADHD drug may help preserve our self-control resources 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
... Society report outlines 21 challenges and needs for global tobacco ... and expertise needed to reduce the rising tide of tobacco ... are the target of the multinational tobacco industry. The report ... issue of CA: A Cancer Journal for Clinicians . ...
... Genital herpes caused by a reactivation of herpes simplex ... lesion in one specific area of the genital region. ... frequently reactivate throughout the genital tract, an important new ... prevention. Now available online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650302 ), the study ...
... is associated with increased cancer risk. The most ... noted for a common form of liver cancer called ... obesity in mice, researchers at the University of California, ... obesity is tumor-promoting and have obtained evidence that this ...
... Hasbro Children,s Research Center and Hasbro Children,s Hospital researchers ... from The Eunice Kennedy Shriver National Institute of Child ... of asthma on the sleep quality and academic performance ... pediatric researchers, led by Daphne Koinis-Mitchell, PhD, to evaluate ...
... reduce the transmission of influenza-like illness during flu season. ... online ( http://www.journals.uchicago.edu/doi/abs/10.1086/650396 ), published in the Feb. 15 ... In an influenza pandemic, vaccination may not be ... is why scientists need to understand how effective other ...
... The BC Centre for Disease Control has launched ... the pandemic H1N1 flu virus has evolved in British ... months. This project capitalizes on BC,s expertise and ... genomes from circulating influenza viruses collected in British Columbia ...
Cached Medicine News:Health News:Global tobacco report outlines 21 challenges for 21st century 2Health News:Global tobacco report outlines 21 challenges for 21st century 3Health News:Study shows genital herpes virus reactivates widely throughout genital tract 2Health News:Link between obesity and enhanced cancer risk elucidated 2Health News:New research will examine link between childhood asthma, sleep and school performance 2Health News:Study finds face masks and hand hygiene can help limit influenza's spread 2Health News:Genomic surveillance of pandemic H1N1 2
Part of the Octopus System which includes both the Starfish & Octopus3. The Starfish Heart Positioner simplifies cardiac positioning and minimizes the associated hemodynamic deterioration when compa...
... way to lift the heart - Guidant's ... 3. The XPOSE 3 is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... Since its U.S. approval in 1992, ABIOMED's ... widely used advanced cardiac assist system in the ... only device approved by the U.S. Food and ... heart failure. ABIOMED continues to make advances ...
... The Arrow LionHeart Left Ventricular Assist ... is designed to be used as a ... end-stage (Class IV) congestive heart failure, for ... The Arrow LionHeart LVAS is not intended ...
Medicine Products: